Fulcrum Therapeutics to Participate in Upcoming Investor Conferences - Sep 08, 2020

支点疗法参与即将召开的投资者会议-2020年9月8日

2020-09-08 20:01:39 BioSpace

本文共723个字,阅读需2分钟

CAMBRIDGE, Mass., Sept. 08, 2020 -- Fulcrum Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences: Virtual H.C. Wainwright 22nd Annual Global Investment Conference Tuesday, September 15, 2020 at 10:00 a.m. ET Morgan Stanley Virtual Global Healthcare Conference Wednesday, September 16, 2020 at 11:00 a.m. ET Cantor Fitzgerald Virtual Global Healthcare Conference Thursday, September 17, 2020 at 4:40 p.m. ET Live audio webcasts of the presentations will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. Archived replays will be available on the Company’s website for 90 days after each conference. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and is advancing losmapimod to Phase 3 for the treatment of COVID-19. Fulcrum also anticipates filing an IND in the third quarter with initiation of a clinical trial in the fourth quarter of 2020 with FTX-6058 for the treatment of sickle cell disease. Please visit www.fulcrumtx.com. Contact: Christi Waarich Director, Investor Relations and Corporate Communications cwaarich@fulcrumtx.com 617-651-8664 Stephanie Ascher Stern Investor Relations, Inc. stephanie.ascher@sternir.com 212-362-1200
马萨诸塞州.、2020年9月8日—— Fulcrum Therapeutics , Inc .,一家专注于改善基因定义罕见疾病患者生活的临床阶段生物制药公司,今天宣布管理层将参加以下虚拟投资者会议: 虚拟 H.C .温赖特第22届全球投资年会 2020年9月15日(星期二)上午10时 摩根斯坦利虚拟全球医疗保健会议 2020年9月16日(星期三)上午11时 Cantor Fitzgerald 虚拟全球保健会议 2020年9月17日(星期四)下午4时40分 演示文稿的实时音频网络广播将通过 Fulcrum 网站的投资者关系部分( https://ir )提供。支点。com /活动和演示文稿。存档的重播将在每次会议后90天内在公司网站上发布。 关于支点疗法 Fulcrum Therapeutics 是一家临床阶段的生物制药公司,专注于改善高未满足医疗需求领域基因界定的罕见疾病患者的生活。Fulcrum 的专有产品引擎确定了能够调节基因表达的药物目标,以治疗已知的基因错误表达的根源。公司已将氯吡莫德推进到治疗阵发性肱肌营养不良症( FSHD )的2期临床开发,正在将氯吡莫德推进到治疗 COVID-19的3期。Fulcrum 还预计将在第三季度提交一份 IND ,并于2020年第四季度开始进行 FTX-6058治疗镰状细胞疾病的临床试验。 请访问 www.支点。 联系方式: Christi Waarich 投资者关系及 企业传讯 cwaarich @ fulcrustx.com 617-651-8664 Stephanie Ascher 斯特恩投资者关系公司. 斯蒂芬妮。asher @ sterr.com 212-362-1200

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文